Regulation of gene expression by WT1 in development and tumorigenesis

International Journal of Hematology

Volumn 76, Issue 2, 2002, Pages 110-116

  Ellisen, Leif W ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Hematopoiesis; Transcription factor; Tumor suppressor; Wilms tumor; WT1

Indexed keywords

WT1 PROTEIN; ISOPROTEIN;

ARTICLE; CARCINOGENESIS; DNA BINDING; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENETIC DATABASE; HUMAN; KIDNEY DEVELOPMENT; MOUSE; NONHUMAN; RNA PROCESSING; SEX DETERMINATION; TRANSCRIPTION INITIATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; METABOLISM; NEPHROBLASTOMA; PHYSIOLOGY; REVIEW;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HUMANS; PROTEIN ISOFORMS; WILMS TUMOR; WT1 PROTEINS;

EID: 0042489185     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982572     Document Type: Article

References (53)

1. Haber D, Housman D. The genetics of Wilms' tumor. Adv Cancer Res. 1992;59:41-68.
2. Little M, Prosser J, Condie A, Smith P, van Heyningen V, Hastie N. Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci U S A. 1992;89:4791-4795.
3. Pelletier J, Bruening W, Kashtan C, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 1991;67:437-447.
4. Bardeesy N, Zabel B, Schmitt K, Pelletier J. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion. Genomics. 1994;21:663-664.
5. Baird P, Santos A, Groves N, Jadresic L, Cowell J. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. Hum Mol Genet. 1992;1:301-305.
6. Kreidberg J, Sariola H, Loring J, et al. WT1 is required for early kidney development. Cell. 1993;74:679-691.
7. Barbaux S, Niaudet P, Gubler M-C, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nature Genet. 1997;17:467-470.
8. Sukhatme V, Cao X, Chang L, et al. A zinc finger encoding gene coregulated with c-fos during growth and differentiation and after cellular depolarization. Cell. 1988;53:37-43.
9. Rauscher F, Morris J, Tournay O, Cook D, Curran T. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science. 1990;250:1259-1262.
10. Nakagama H, Heinrich G, Pelletier J, Housman D. Sequence and structural requirements for high-affinity binding by the WT1 gene product. Mol Cell Biol. 1995;15:1489-1498.
11. Lee S, Huang K, Palmer R, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999;98:663-673.
12. Englert C, Vidal M, Maheswaran S, et al. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A. 1995;92:11960-11964.
13. Bruening W, Moffett P, Chia S, Heinrich G, Pelletier J. Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. FEBS Lett. 1996;393:41-47.
14. Reddy J, Morris J, Wang J, et al. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem. 1995;270:10878-10884.
15. Holmes G, Boterashvili S, English M, Wainwright B, Licht J, Little M. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins. Biochem Biophys Res Commun. 1997;233:723-728.
16. Wang Z-Y, Qiu Q-Q, Deuel T. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem. 1993;268:9172-9175.
17. Wang ZY, Qiu QQ, Huang J, Gurrieri M, Deuel TF. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene. 1995;10:415-422.
18. Madden S, Cook D, Morris J, Gashler A, Sukhatme V, Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science. 1991;253:1550-1553.
19. Hewitt S, Saunders G. Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function. Anticancer Res. 1996;16:621-626.
20. Natoli T, McDonald A, Alberta J, Taglienti M, Housman D, Kreidberg J. A mammal-specific exon of WT1 is not required for development or fertility. Mol Cell Biol. 2002;22:4433-4438.
21. Kent J, Coriat A, Sharpe P, Hastie N, van Heyningen V. The evolution of WT1 sequence and expression pattern in the vertebrates. Oncogene. 1995;11:1781-1792.
22. Laity J, Dyson H, Wright P. Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein. Proc Natl Acad Sci U S A. 2000;97:11932-11935.
23. Larsson S, Charlieu J, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 1995;81:391-401.
24. Caricasole A, Duarte A, Larsson S, et al. RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci U S A. 1996;93:7562-7566.
25. Kennedy D, Ramsdale T, Mattick J, Little M. An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling. Nature Genet. 1996;12:329-332.
26. Haber D, Sohn R, Buckler A, Pelletier J, Call K, Housman D. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A. 1991;88:9618-9622.
27. Bruening W, Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem. 1996;271:8646-8654.
28. Scharnhorst V, Dekkar P, van der Eb AJ, Jochemsen A. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. J Biol Chem. 1999;274:23456-23462.
29. Drummond I, Badden S, Rohwer-Nutter P, Bell G, Sukhatme V, Rauscher FJ III. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science. 1992;257:674-678.
30. Werner H, Rauscher FJ III, Sukhatme V, Drummond I, Roberts C, LeRoith D. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem. 1994;269:12577-12582.
31. Gashler A, Bonthron D, Madden S, Rauscher FJ III, Collins T, Sukhatme V. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci U S A. 1992;89:10984-10988.
32. Wang Z, Qiu Q, Enger K, Deuel T. A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. Proc Natl Acad Sci U S A. 1993;90:8896-8900.
33. Maheswaran S, Park S, Bernard A, et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A. 1993;90:5100-5104.
34. Reddy J, Hosono S, Licht J. The transcriptional effect of WT1 is modulated by choice of expression vector. J Biol Chem. 1995;270:29976-29982.
35. English MA, Licht JD. Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control. J Biol Chem. 1999;274:13258-13263.
36. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 1995;14:4662-4675.
37. Nachtigal M, Hirokawa Y, Enyeart-VanHouten D, Flanagan J, Hammer G, Ingraham HA. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell. 1998;93:445-454.
38. Cook DH, Hinkes M, Bernfield M, Rauscher FJ III. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene. 1996;13:1789-1799.
39. Palmer R, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber D. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol. 2001;11:1805-1809.
40. Hosono S, Gross I, English M, Hajra K, Fearon E, Licht J. E-cadherin is a WT1 target gene. J Biol Chem. 2000;275:10943-10953.
41. Kim J, Prawitt D, Bardeesy N, et al. The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol. 1999;19:2289-2299.
42. Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J. 1999;18:3990-4003.
43. Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 1997;57:1429-1434.
44. Maurer U, Jehan F, Englert C, et al. The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor (VDR). J Biol Chem. 2001;276:3727-3732.
45. Thate C, Englert C, Gessler M. Analysis of WT1 target gene expression in stably transfected cell lines. Oncogene. 1998;17:1287-1294.
46. Ellisen L, Carlesso N, Cheng T, Scadden D, Haber D. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20:1897-1909.
47. Wang W, Lee S, Palmer R, Ellisen L, Haber D. A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J Biol Chem. 2001;276:16810-16816.
48. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber D. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995;9:2143-2156.
49. Davies R, Calvio C, Bratt E, Larsson S, Lamond S, Hastie N. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev. 1998;12:3217-3225.
50. Ladomery M, Slight J, McGhee S, Hastie N. Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear poly(A)(+) ribonucleoprotein. J Biol Chem. 1999;274:36520-36526.
51. Bardeesy N, Pelletier J. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res. 1998;26:1784-1792.
52. Hammes A, Guo J-K, Lutsch G, et al. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron development. Cell. 2001;106:319-329.
53. Hossain A, Saunders G. The human sex-determining gene SRY is a direct target of WT1. J Biol Chem. 2001;276:16817-16823.